Related Experiment Video
Updated: Aug 29, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
RFC5 and STAT3 form a transcriptional complex to drive NSCLC progression via c-Myc
Jinhua Yan1,2, Tao Yi2, Wentao Tian3
1Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China.
Abstract:
Non-small cell lung cancer (NSCLC), a leading cause of cancer death worldwide, is often characterized by late diagnosis and treatment resistance, which adversely affect patient prognosis. This study identified replication factor C subunit 5 (RFC5) as a critical oncoprotein in NSCLC progression. Single-cell transcriptomic analysis of multi-stage NSCLC tissues revealed RFC5 as the most specific marker for a highly proliferative and migratory tumor subpopulation. RFC5 promoted NSCLC malignant phenotypes. Mechanistically, RFC5 interacted with and activated STAT3, functioning as a co-transcriptional activator to upregulate the expression of the oncogene c-Myc. Furthermore, GATA3 acts as an upstream negative regulator of RFC5. Collectively, this study revealed that RFC5 exerted a co-transcriptional activation function, which was negatively regulated by GATA3, to promote NSCLC progression by activating the STAT3-c-Myc signaling pathway. Thus, RFC5 represented a promising prognostic biomarker and therapeutic target for NSCLC.
Related Concept Videos
Master Transcription Regulators
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Induced Pluripotent Stem Cells
Somatic cells are...
Co-activators and Co-repressors

